ArticlePloS one2020
Urinary tract infection in cancer patients and antimicrobial susceptibility of isolates in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Ciprofloxacin resistance in community and hospital-acquired urinary tract infections: a systematic review and meta-analysis from African population.BMC infectious diseases · 2025Pooled it
- Global prevalence and etiologies of urinary tract infection among oncologic patients: a systematic review and meta-analysis.World journal of urology · 2025Pooled it
- Descriptive Epidemiology ofBioMed research international · 2025Pooled it
- Progress on implementing the WHO-GLASS recommendations on priority pathogen-antibiotic sensitivity testing in Africa: AWellcome open research · 2024Pooled it
- Bacterial profile, antimicrobial resistance patterns and associated factors among cancer patients at Hawassa University Comprehensive Specialized Hospital, Sidama region, Southern Ethiopia.BMC infectious diseases · 2026Article
- Molecular Characterization and Antibiotic Resistance of Broad-SpectrumInternational journal of microbiology · 2026Article
- Antimicrobial susceptibility patterns and associated risk factors of bacterial isolate among urinary tract infection suspected patients at University of Gondar Comprehensive Specialized Hospital North west Ethiopia.BMC infectious diseases · 2025Article
- Investigation of antimicrobial susceptibility patterns, risk factors and their impact on mortality in cancer patients at a tertiary care cancer hospital- A prospective study.Annals of clinical microbiology and antimicrobials · 2024Article
- Antimicrobial resistance and ESBL production in uropathogenicJAC-antimicrobial resistance · 2024Review
- Antimicrobial susceptibility testing data analysis over 3 years at the Yaoundé General Hospital, Cameroon.JAC-antimicrobial resistance · 2024Article
- Host-Pathogen Interactions inDiagnostics (Basel, Switzerland) · 2024Article
- Article
- Extended-spectrum beta-lactamase-producing Enterobacteriaceae related urinary tract infection in adult cancer patients: a multicenter retrospective study, 2015-2019.BMC infectious diseases · 2023Article
- Urine microbiome in individuals with an impaired immune system.Frontiers in cellular and infection microbiology · 2023Review
- Prevalence and Predictors of Multi-Drug Resistant Organisms Among Ambulatory Cancer Patients with Urinary Tract Infections.Infection and drug resistance · 2023Article
- Diagnostic value of different urine tests for urinary tract infection: a systematic review and meta-analysis.Translational andrology and urology · 2022Article
- Bacterial uropathogens and burden of antimicrobial resistance pattern in urine specimens referred to Ethiopian Public Health Institute.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections are the most common causes of morbidity and mortality in patients with cancer. The emergence of multiple-drug-resistant (MDR) strains of gram-negative bacteria causing urinary tract infection has become a serious concern in cancer patients. Therefore, the present study aimed to determine the spectrum and antibiotic resistance pattern of bacterial isolates related to urinary tract infections among cancer patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. METHODS AND MATERIALS: Hospital based prospective cross-sectional study was conducted for three months from January to March 2018 in tertiary care hospital located in the capital city of the country. Gram-negative bacteria isolated from urine specimens from hospitalized patients with cancer were characterized using standard microbiological methods. Modified Kirby-Bauer disk diffusion technique was applied for antimicrobial susceptibility testing in accordance with CLSI 2019 criteria.
resultsOf totally 292 urine samples tested, eighteen (6.3%) were culture positive cases, Escherichia coli (44.4%) was the highest proportion isolated uropathogen followed by Klebsiella pneumoniae (22.2%) and Citrobacter diversus (16.7%). The antibiotic susceptibility results showed meropenem and nitrofurantoin as the most effective antibiotics for E. coli, K. pneumoniae, and Citrobacter diversus isolates. The rate of multidrug resistant (MDR) isolates were 33.3% (6/18), and meropenem and nitrofurantoin were the most effective antibiotic against MDR isolates.
conclusionThe study findings showed a significant distribution of MDR gram-negative bacteria which may increase the burden of urinary tract associated infections in cancer patients. Carbapenem (meropenem) can be considered as effective agents to treat MDR cases in our region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.